Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Respir Dis
Egile Nagusiak: Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://ncbi.nlm.nih.gov/pubmed/32066332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak